Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

The promise of patient-centered biotechnology

James Geraghty, JD
Meds
December 22, 2022
1 Shares
Share
Tweet
Share

An excerpt from Inside The Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology.

Pre-revolutionary stirrings

Every revolution rises up against an order in need of reform. For the orphan drug revolution, that order was the pharmaceutical industry of the 1970s. Most pharma companies had been founded by entrepreneurial chemists or pharmacists decades or even centuries earlier. But as those early firms underwent many mergers and grew into large public companies, more financially trained managers took over—and their priorities veered inexorably away from innovation and risk-taking toward the pursuit of predictable profitability. In the 1970s, the industry faced in addition the much more rigorous and expensive testing of experimental drugs to prove safety and efficacy imposed by the Kefauver–Harris amendments described earlier. Phil Reilly summarized the effect in Orphan: The Quest to Save Children with Rare Genetic Disorders: “Pharmaceutical companies responded by focusing on developing treatments for common diseases in order to maximize the possibility of recouping research and development costs and generating significant profits. As a result, rare diseases were largely ignored due to poor economic potential and were thus said to be ‘orphaned.'” Those developments created a consuming hunt for low-risk blockbusters, or billion-dollar drugs. For pharma, those came ideally from minor but patentable changes to existing drugs, “pills in a bottle” easily sold by large promotional sales forces for common but not overly complex diseases. An ulcer drug, Tagamet, became the first $1 billion-a-year blockbuster in 1977; a marginally improved drug, Zantac, reached $2 billion soon after. Pharma industry giants chased “me-too” drugs that added progressively less medical value but progressively larger sales.

This dynamic culminated in the fevered pursuit of lipid-lowering statin drugs, until Lipitor, the fifth drug in the class, with outcomes only modestly better than earlier versions, reached more than $12 billion in yearly sales. Roots in science, medicine, and entrepreneurship Every revolution also grows out of deep roots. Those of the orphan drug revolution lay in science, medicine, and entrepreneurship. Its scientific roots grew from one of the most celebrated discoveries of the twentieth century, the deciphering of “the secret of life”—the biochemical basis of genetic reproduction, the double helix structure of the DNA molecule—by Watson and Crick at Cambridge University in 1953. Their work triggered an unprecedented explosion of biomedical research. Initially researchers rushed to figure out how to “read” the genetic code. Frederick Sanger won the first of two Nobel Prizes for discoveries of how to read protein DNA sequences in 1958. Prizes followed in the 1960s for unraveling the genetics behind enzymes, viruses, and proteins. Then in 1973, Stanley Cohen and Herbert Boyer laid the foundations for biotechnology with the invention of a way to reproduce human genes in bacterial cells. These modified cells became living factories, producing functional human proteins that could serve to replace defective ones—and inspired the founding of the first wave of biotechnology companies. Initially unconnected roots in the field of medical genetics were emerging in parallel. As Phil Reilly recounts in Orphan: The Quest to Save Children with Rare Genetic Disorders, pioneering work identifying single-gene disorders was begun in England in the early 1900s.The first compendium of genetic diseases, published by New York’s Cold Spring Harbor Laboratory in 1911, included more than 100 “monogenic” diseases, and the study of genetic diseases took off.

***

Roscoe Brady perseveres to a therapy 

The intertwining of these roots of science, medicine, and entrepreneurship is nowhere better illustrated than in the legacy of Roscoe Brady. A visionary physician-scientist, Brady developed a drug that drew on advances in both medical genetics and genetic engineering and would be brought to approval by a biotech entrepreneur. Brady’s research built most directly on work by the Belgian biochemist Christian deDuve. In 1955, deDuve discovered previously unknown structures in cells, which he called lysosomes, which contain digestive enzymes that play a critical role in storing and decomposing cellular materials. For the far-reaching impact these have on lysosomal storage disorders and other conditions, de Duve was with two colleagues awarded the Nobel Prize in Physiology or Medicine in 1974.

Brady was able to locate the causes of several of these lysosomal storage diseases (or LSDs, an acronym coined before it became fashionable elsewhere), including Gaucher, Fabry, and Niemann–Pick diseases. Gaucher disease came first, for Brady and for the orphan drug revolution. First identified by French physician Philippe Gaucher in the 1880s, the disease interferes with the function of the liver, spleen, and bone marrow and can lead for many patients to early death. In 1964, Brady discovered that the lack of a specific enzyme, called glucocerebrosidase, resulted in fatty material collecting in these organs and caused the severe clinical symptoms. Brady soon raised the possibility of treating the disease by giving patients the missing enzyme. He and his collaborators found a way to extract trace amounts of enzyme from human placental tissue, which develops in a uterus during pregnancy and is expelled after a baby is born. They tested small amounts in animal models that simulated Gaucher disease and saw evidence it was working. In 1973, they were able to get enough of the enzyme to test it in a few patients. Brady attracted a talented group at the NIH and beyond, with team members like Norm Barton, Ed Kolodny, Pram Mistry, and Scott Furbish leading Gaucher clinical work. They gave patients millions of units of the enzyme, but at first it showed no effect. After realizing that the enzyme wasn’t getting absorbed well enough to work, they came up with a way to chemically tweak the enzyme so it would be better absorbed. That form, called alglucerase, worked significantly better, and the foundation for a therapy was laid. Brady, who many felt should have also won the Nobel Prize, is—like so many others who didn’t—little known beyond those benefiting from his work. But by laying the groundwork for a family of genuinely pathbreaking therapies, his work has immensely improved the lives of thousands.

James Geraghty is a health care executive and author of Inside The Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology.

Prev

The holidays can open up a range of emotions

December 22, 2022 Kevin 0
…
Next

Psychic numbing: Why we would prefer to save a single dog instead of thousands of humans

December 22, 2022 Kevin 0
…

Tagged as: Medications

Post navigation

< Previous Post
The holidays can open up a range of emotions
Next Post >
Psychic numbing: Why we would prefer to save a single dog instead of thousands of humans

Related Posts

  • The impact of panels early in medical school on informing patient-centered care

    Sangrag Ganguli and Varun Mehta
  • Redefining quality through a patient-centered approach

    Anne Zink, MD
  • The tiny gains of patient-centered medical homes. Are they worth it?

    Richard Young, MD
  • A universal patient medical record

    Michael R. McGuire
  • A patient waits. And waits.

    Michele Luckenbaugh
  • Treating the patient’s body is not synonymous with treating the patient

    Steven Zhang, MD

More in Meds

  • The deadly consequences of a shortage: The Pluvicto crisis leaves metastatic prostate cancer patients in limbo

    Matt Drewes
  • The real story of Xylazine contamination in street fentanyl and how we can manage it

    Julie Craig, MD
  • The cannabis education gap: Why patients are left in the dark

    Timothy Byars
  • Are doctors ready to discuss psychedelic therapies with patients?

    Thaís Salles Araujo, MD
  • The rise and dark side of fungi: Exploring health benefits and pathogenic threats

    Sandra Vamos, EdD and Deanna Lernihan, MPH
  • Advocacy and collaboration lead to major patient safety benefits on sterile pharmaceutical compounding: a review of USP’s revisions to Chapter <797>

    Elizabeth Rebello, MD
  • Most Popular

  • Past Week

    • A patient’s perspective on the diminishing relationship between doctors and patients

      Michele Luckenbaugh | Conditions
    • Unmasking wage disparity in health care: the truth behind the Elmhurst Hospital physician strike

      Kevin Pho, MD | KevinMD
    • Why affirmative action is crucial for health equity and social justice in medicine

      Katrina Gipson, MD, MPH | Policy
    • How electronic health records preserve patients’ legacies in the words of oncologists

      Marc Braunstein, MD, PhD | Physician
    • Unmasking the brutal reality of gun violence in America: a call to action for unity and meaningful change

      Osmund Agbo, MD | Policy
    • Emulating Michael Jordan’s winning mindset: a path to success for health care professionals and entrepreneurs

      Harvey Castro, MD, MBA | Physician
  • Past 6 Months

    • The growing threat to transgender health care: implications for patients, providers, and trainees

      Carson Hartlage | Policy
    • Breaking point: the 5 reasons American doctors are dreaming of walking away from medicine

      Amol Shrikhande, MD | Physician
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
  • Recent Posts

    • Why doctors aren’t to blame for the U.S. opioid crisis [PODCAST]

      The Podcast by KevinMD | Podcast
    • Raw humanity on night float: inspiring patient encounters and overcoming challenges

      Johnathan Yao, MD, MPH | Physician
    • Is AI the solution for the shortage of nephrologists? ChatGPT weighs in.

      Amol Shrikhande, MD | Tech
    • Unlocking the secrets of cancer conferences: an end-of-life counselor’s journey among pharmaceutical giants

      Althea Halchuck, EJD | Conditions
    • Why HIPAA is failing and what you need to know to protect your data [PODCAST]

      The Podcast by KevinMD | Podcast
    • Revolutionizing emergency medicine: Overcoming long-term challenges with innovative solutions for physicians and patients

      Anonymous | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • What Drug Did FDA Just Approve for COVID?
  • PET Scan for Alzheimer's Dx; Predicting Colon Cancer Survival
  • What Happens When We Classify Kids' Weight as a 'Disease'?
  • Sotagliflozin Gets FDA's Blessing for Heart Failure
  • Cardiorespiratory Monitoring Can Be Telling of Outcomes in Extremely Preterm Infants

Meeting Coverage

  • No Access to Routine Healthcare Biggest Barrier to HPV Vaccination
  • Trial Results Spark Talk of Curing More Metastatic Cervical Cancers
  • Cross-Border Collaboration Improves Survival in Pediatric Leukemia Patients
  • Monoclonal Antibody Reduced Need For Transfusions in Low-Risk MDS
  • Less-Invasive Surgery for Pancreatic Cancer Proves Safe, Effective
  • Most Popular

  • Past Week

    • A patient’s perspective on the diminishing relationship between doctors and patients

      Michele Luckenbaugh | Conditions
    • Unmasking wage disparity in health care: the truth behind the Elmhurst Hospital physician strike

      Kevin Pho, MD | KevinMD
    • Why affirmative action is crucial for health equity and social justice in medicine

      Katrina Gipson, MD, MPH | Policy
    • How electronic health records preserve patients’ legacies in the words of oncologists

      Marc Braunstein, MD, PhD | Physician
    • Unmasking the brutal reality of gun violence in America: a call to action for unity and meaningful change

      Osmund Agbo, MD | Policy
    • Emulating Michael Jordan’s winning mindset: a path to success for health care professionals and entrepreneurs

      Harvey Castro, MD, MBA | Physician
  • Past 6 Months

    • The growing threat to transgender health care: implications for patients, providers, and trainees

      Carson Hartlage | Policy
    • Breaking point: the 5 reasons American doctors are dreaming of walking away from medicine

      Amol Shrikhande, MD | Physician
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
  • Recent Posts

    • Why doctors aren’t to blame for the U.S. opioid crisis [PODCAST]

      The Podcast by KevinMD | Podcast
    • Raw humanity on night float: inspiring patient encounters and overcoming challenges

      Johnathan Yao, MD, MPH | Physician
    • Is AI the solution for the shortage of nephrologists? ChatGPT weighs in.

      Amol Shrikhande, MD | Tech
    • Unlocking the secrets of cancer conferences: an end-of-life counselor’s journey among pharmaceutical giants

      Althea Halchuck, EJD | Conditions
    • Why HIPAA is failing and what you need to know to protect your data [PODCAST]

      The Podcast by KevinMD | Podcast
    • Revolutionizing emergency medicine: Overcoming long-term challenges with innovative solutions for physicians and patients

      Anonymous | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...